A Cost- and Environmentally Effective Approach to Supplying Nitrogen Gas to Pharmaceutical Manufacturing Industrial Facilities - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Cost- and Environmentally Effective Approach to Supplying Nitrogen Gas to Pharmaceutical Manufacturing Industrial Facilities
The authors argue that the cost of generating nitrogen via an in-house gas generator is considerably lower than the cost of using fractional distillation to generate liquid nitrogen.


Pharmaceutical Technology
Volume 34, Issue 7

Employing pressure-swing adsorption in an industrial setting


Figure 1: Schematic of a typical two-vessel pressure-swing-adsorption system for in-house generation of nitrogen. (FIGURES COURTESY OF INDUSTRIAL NITROGEN PRODUCTS, FILTRATION AND SEPARATION DIVISION, PARKER HANNIFIN)
An overall schematic diagram of an in-house PSA generator for creating industrial-scale quantities of nitrogen is shown in Figure 1. Instrument-quality compressed air (110–140 psig at room temperature) is used as a feedstock that is first filtered, dried (using a refrigerated air dryer) and then filtered again using a coalescing filter to remove any particulate matter, oils, and other liquids to protect the carbon bed and valves from contamination and to optimize the process. These filters are equipped with automatic float drains to empty collected liquids. The purified air is then passed into an air surge tank (labeled AST101 in Figure 1) to protect the air compressor and dryer from the cyclic air demand of the PSA unit.

The heart of the system is a pair of adsorption vessels that are loaded with carbon molecular sieve (CMS). The CMS generates nitrogen, which is collected in the nitrogen storage tank (labeled NST101 in Figure 1). Because the adsorption vessels operate on an alternating basis, one vessel is in the absorption cycle while the other vessel is in the desorption cycle.

The overall control of the generator is performed by a programmable logic controller (PLC) that automatically opens and closes solenoid valves that pneumatically activate the process valves that control the air and nitrogen flow. At a given time, one of the two air-inlet valves is open to allow air to flow into a vessel to begin its adsorption cycle, and the exit valve for that chamber is opened to allow the nitrogen to leave the vessel while the absorption of oxygen is occurring. At the end of the cycle (which is user settable, typically one minute), valves will open to allow for pressure equalization for 4 s. After equalization, the air-inlet valve and nitrogen-outlet valve for the other vessel will open and the vessel that had just been used will be allowed to go into a desorption cycle. Since one of the two adsorption vessels is open (except for the 4 s equalization time), a continuous flow of nitrogen is produced. After the nitrogen is generated, it passes through a final filter that removes particulate contamination with an efficiency of 99.9999% at 0.01 μm. An output flow meter and flow control valve are provided to control the desired flow rate. In many instances, an auxiliary storage tank is employed to provide constant pressure to the process, even during pressure equalization.

The flow rate of the inlet gas is the primary determinant of the purity of the nitrogen. At a low flow rate, higher-purity nitrogen will be generated; typically, a PSA system can generate 95–99.999% pure nitrogen depending on the flow rate. Each system is configured to provide the nitrogen purity required by the application, and an oxygen analyzer is employed to monitor the oxygen content (the nitrogen is sampled from the nitrogen storage tank).

The nitrogen that is produced by a PSA generator contains approximately 1% argon as this inert gas is not retained by the CMS (sea-level composition of air is 0.934% argon) and is not a problem for the manufacturing process since it will not react with compounds of pharmaceutical interest. The nitrogen purity from a PSA generator is frequently defined by the residual oxygen content (e.g., 1% oxygen in product gas is equivalent to 99% nitrogen and argon).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here